These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31583610)

  • 1. An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions.
    Joshi S; Gudi G; Menon VCA; Tandon M; Joshi V; Suryawanshi S; Barkate H; Sawant N; Katare S; Siddique W
    Clin Pharmacokinet; 2020 Mar; 59(3):349-357. PubMed ID: 31583610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
    Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
    BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
    Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
    BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
    Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
    Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
    Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
    BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remogliflozin Etabonate: First Global Approval.
    Markham A
    Drugs; 2019 Jul; 79(10):1157-1161. PubMed ID: 31201711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional gastrointestinal delivery of remogliflozin etabonate in humans.
    O'Connor-Semmes RL; Sandefer EP; Hussey EK; Tao W; Doll WJ; Page RC; Dobbins R
    Biopharm Drug Dispos; 2013 Mar; 34(2):79-86. PubMed ID: 23111980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
    Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Bioequivalence Evaluation of Two Montelukast Sodium Chewable Tablets in Healthy Chinese Volunteers Under Fasted and Fed Conditions.
    Li W; Wang Y; Pei Y; Xia Y
    Drug Des Devel Ther; 2021; 15():1091-1099. PubMed ID: 33727797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study.
    Chen G; Zhang D; Du A; Zhang Y; Zhang Y; Zhang L; Zang S; Liu X; Wang Z; Zhen H; Liu Y; Yang S; Wang J
    Pharmacotherapy; 2020 Jul; 40(7):623-631. PubMed ID: 32498113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
    O'Connor-Semmes R; Walker S; Kapur A; Hussey EK; Ye J; Wang-Smith L; Tao W; Dobbins RL; Cheatham B; Wilkison WO
    Drug Metab Dispos; 2015 Jul; 43(7):1077-83. PubMed ID: 25934577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
    Dobbins RL; O'Connor-Semmes R; Kapur A; Kapitza C; Golor G; Mikoshiba I; Tao W; Hussey EK
    Diabetes Obes Metab; 2012 Jan; 14(1):15-22. PubMed ID: 21733056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
    Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
    Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
    Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
    Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions.
    Li X; Zhang H; Zhu X; Li C; Chen H; Liu J; Chen G; Wu M; Liu C; Shen Z; Niu J; Liu B; Ding Y
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):434-442. PubMed ID: 30049304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Clin Drug Investig; 2023 Oct; 43(10):785-797. PubMed ID: 37798608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.